

CASE REPORT

Open Access

# 1031-1034delTAAC (Leu125Stop): a novel familial *UBE3A* mutation causing Angelman syndrome in two siblings showing distinct phenotypes

Greice Andreotti De Molfetta<sup>1,2,4\*</sup>, Cristiane Ayres Ferreira<sup>2</sup>, Daniel Onofre Vidal<sup>2</sup>, Liane de Rosso Giuliani<sup>3</sup>, Maria José Maldonado<sup>3</sup> and Wilson Araujo Silva Jr<sup>1,2,4</sup>

## Abstract

**Background:** More than 50 mutations in the *UBE3A* gene (E6-AP ubiquitin protein ligase gene) have been found in Angelman syndrome patients with no deletion, no uniparental disomy, and no imprinting defect.

**Case Presentation:** We here describe a novel *UBE3A* frameshift mutation in two siblings who have inherited it from their asymptomatic mother. Despite carrying the same *UBE3A* mutation, the proband shows a more severe phenotype whereas his sister shows a milder phenotype presenting the typical AS features.

**Conclusions:** We hypothesized that the mutation Leu125Stop causes both severe and milder phenotypes. Potential mechanisms include: i) maybe the proband has an additional problem (genetic or environmental) besides the *UBE3A* mutation; ii) since the two siblings have different fathers, the *UBE3A* mutation is interacting with a different genetic variant in the proband that, by itself, does not cause problems but in combination with the *UBE3A* mutation causes the severe phenotype; iii) this *UBE3A* mutation alone can cause either typical AS or the severe clinical picture seen in the proband.

**Keywords:** Angelman syndrome, *UBE3A* gene, Imprinting, Novel mutation, Distinct phenotypes, HRM

## Background

Angelman syndrome (AS) is a neuro-genetic disorder characterized by intellectual and developmental delay, sleep disturbance, seizures, jerky movements, frequent laughter or smiling and a happy disposition [1]. The incidence of AS is estimated to be between 1/10,000 and 1/20,000 [2] and is inherited in an autosomic dominant trait, modified by imprinting, or inherited by imprinting [3]. Analysis of parent-specific DNA methylation pattern in the 15q11-13 chromosome region detects approximately 77% of individuals with AS, including those cases with a deletion (approximately 70%), uniparental disomy (1-2%), or an imprinting defect (3-5%); fewer than 1% of individuals have a cytogenetically chromosome rearrangement and *UBE3A* sequencing detects mutations in approximately 5-

10% of the patients [4]. In 10-15% of the cases the molecular exam is normal with no deletions, uniparental disomy, imprinting defects or *UBE3A* mutations [5]. Recently, it was demonstrated that the Angelman syndrome protein Ube3A is a neuronal activity-regulated protein that controls synaptic function by ubiquitinating and degrading the synaptic protein Arc. In the absence of Ube3A, elevated levels of Arc accumulate in neurons resulting in the excessive internalization of AMPA receptors at synapses and impaired synaptic function [6]. We report a brother and sister who was referred to our laboratory in order to investigate a clinical suspicion of AS. As the analysis of the differential parental specific DNA methylation within the 15q11-13 region was normal, we investigated the *UBE3A* gene in order to screen for mutations causing AS. We here describe a novel *UBE3A* frameshift mutation in two siblings who have inherited it from their asymptomatic mother. Despite carrying the same *UBE3A* mutation, the proband shows a more severe phenotype whereas his sister shows the typical AS features associated to a milder phenotype.

\* Correspondence: gamolf@fmrp.usp.br

<sup>1</sup>Department of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil

<sup>2</sup>Regional Blood Center of Ribeirao Preto and National Institute of Science and Technology in Cell Therapy, Ribeirao Preto, Brazil

Full list of author information is available at the end of the article

## Case presentation

### Case report

Patient 1, the proband, aged 14 years and 8 months, was born from non-consanguineous and healthy parents (Figure 1A). After a normal pregnancy, the patient was born at term by cesarean section, weighing 2,900 g (25th-50th centile), length and head circumference were not informed. His developmental progress was delayed; he sat at 1 year old, he is not able to walk. At the age of 9 months, he began to have seizures and has been on valproic acid with good control. Unlike typical AS patients, he did not display a happy disposition with frequent smiling and laughing. He has normal EEG and brain MRI shows reduction of the volume of the inferior cerebellar vermis, increase of the cisterna magna, diffuse atrophy with decreased volume more pronounced in the fronto-temporal region, ventriculomegaly, thin corpus callosum. When he was examined at the age of 11 years old, his head circumference was 47 cm (<3th centile), height and weight were not informed. He presented with normal cytogenetic analysis and normal study of the methylation within the 15q11-13 region.

Patient 2, the proband's sister, aged 6 years and 3 months, was born from non-consanguineous and healthy parents (Figure 1B); these two siblings have different fathers (Figure 2). The prenatal period was uneventful and the baby was delivered by cesarean section at full term with a birth weight of 3385 g (50<sup>th</sup>-75<sup>th</sup> centile), height of 50 cm (50<sup>th</sup>-75<sup>th</sup> centile), and head circumference of 35 cm (75<sup>th</sup>-90<sup>th</sup> centile). Her developmental progress was delayed. She presented hypotonia by age of 7 months, sat at 2 years old, walked at 3 years old. At the age of 3 years old, she began to have seizures and has been on fenobarbital with good control. She has the typical AS phenotype, happy behavior, wide mouth with wide-spaced teeth, uplifted flexed arm position, ataxic gait, and excessive devotion for playing with water. When she was examined at the age of 4 years old, her head circumference was 47.5 cm (<3th centile), height 110 cm (97th centile), and weight

20.000g (95th centile). She presented the typical EEG for AS patients, normal brain MRI, normal cytogenetic analysis and study of the methylation within the 15q11-13 region.

### Methods

#### DNA extraction

The genomic DNA was extracted from leukocytes from peripheral blood samples, using Super Quick-gene-rapid DNA isolation (Promega), following the manufacturer's instructions.

#### Methylation analysis using Methylation Sensitive High Resolution Melting (MS-HRM) assay


For methylation analysis of the *SNRPN* gene, DNA conversion using bisulfite and cleanup of 2 µg of genomic DNA was carried out using EpiTect Bisulfite Kit (Qiagen), following the manufacturer's instructions. Afterwards the DNA conversion, each sample was run in duplicate by the MS-HRM assay to determine the methylation pattern within the 15q11-13 region using primers and protocol described by White et al. (2007) [7]. The MS-HRM analysis was performed in a 7500 Fast Real-Time PCR System (Applied Biosystems) using MeltDoctor HRM Master Mix (Applied Biosystems) according manufacturer's instructions. The PCR reaction conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 58°C for 1 minute and 95°C for 1 minute, followed by the standard melting curve.

#### PCR and mutation screening using High Resolution Melting (HRM) assay

In order to screen for *UBE3A* mutations, we used the primers described by Malzac et al. (1998) [8] and the HRM technique. The HRM analysis was performed in a 7500 Fast Real-Time PCR System (Applied Biosystems) using MeltDoctor HRM Master Mix (Applied Biosystems) according manufacturer's instructions. Each sample was run in duplicate and approximately 20 ng of genomic DNA was amplified in a total volume of 20 µl containing 5 µM of



**Figure 1** Patients here reported. In **A**) we observe the proband clinical features; In **B**) we observe the proband's sister clinical features.



each primer, deionized water, and 10µl of MeltDoctor master mix (Applied Biosystems). The PCR reaction conditions were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, 55°C for 1 minute and 95°C for 1 minute, followed by the standard melting curve.


#### Cloning and DNA sequencing

DNA fragments amplified by PCR were subjected to direct sequencing in an automatic capillary sequencing system ABI 3130 Genetic Analyser using BigDye<sup>R</sup> Terminator v3.1 Cycle Sequencing kit, following the manufacturer's instructions. The sequencing results were analyzed through FinchTV version 1.4.0 (Geospiza Inc. 2004–2006); the sequences obtained were compared with reference from the GenBank (NM\_130.839.1). In order to properly characterize the mutation, the same DNA fragments amplified by PCR were cloned into TOPO<sup>R</sup> vector using TOPO TA cloning (Invitrogen) according to manufacturer's instructions.

#### Conclusions

Kubota et al., (1997) [9] have developed a methylation-specific PCR assay for detection of the PWS and AS based on the methylation status of the CpG island within the SNRPN gene. More recently a similar protocol was developed based on comparing melting profiles of experimental samples to melting profiles from DNA with known methylation levels. This assay is called Methylation Sensitive HRM (MS-HRM) [10] and is also employed to analyze the differential methylation at the SNRPN locus [7]. Carrying on our methylation experiments by using the MS-HRM protocol, analysis of samples from the two siblings with AS phenotype and their asymptomatic mother (Figure 2) revealed a normal methylation pattern (Figure 3A), excluding the possibility of deletion, uniparental disomy or imprinting mutation encompassing the *SNRPN* locus. In

order to characterize the molecular defect, the entire coding region of *UBE3A* gene was screened for mutations using the HRM method. The result revealed that exon 9 of both siblings and their mother share an abnormal pattern of melt curve when compared with the control (Figure 3B). Afterwards, the DNA sequencing of exon 9 showed a deletion of four nucleotides (TAAC) affecting codons 125 and 126 resulting in a frameshift mutation, which creates a premature stop codon at position 125, 1031-1034delTAAC (Leu125Stop) (Figure 4). In this scenario, we concluded that the mutation was transmitted from a paternal chromosome inherited from the mother. The majority of mutations found within *UBE3A* gene are localized at the *hect* domain region, which includes the 3' region of the exon 9, extends through the exon-16. All of them are frameshift mutations leading to stop codons [11-15]. The mutation described in the present study is localized at the beginning of exon 9 causing a frameshift mutation changing the entire *hect* domain. Hui-bregtse et al. (1995) [16] have previously reported that a *UBE3A* mutant protein lacking the last six amino acids is completely defective in ubiquitination. Thus, we predict that the protein product from the mutated *UBE3A* reported here will also be completely defective in ubiquitination. We report here that in spite of carrying the same mutation, the proband shows a more severe phenotype as he is not able to walk and does not present some of the typical AS facial features as wide mouth with wide-spaced teeth, happy behavior, arm positions and movements. Also, he presents abnormal MRI showing severe abnormalities which are not the typical MRI findings for AS. On the other hand, his sister presents a milder phenotype, compared to her brother, including the typical AS features as wide mouth and spaced teeth, ataxic gait, arm movements, happy behavior, attraction to water. It has already been reported that *UBE3A* mutations resulting in



frameshifts and/or premature truncations give a more severe phenotype than missense mutations or short in-frame deletions that still allow the translation of a full-length protein [4]. Baumer et al. (1999) [14] have reported that patients with *UBE3A* mutations and deletions present a more severe phenotype as the patient shows all the clinical features and, the milder phenotype is reported among patients carrying paternal uniparental disomy and

imprinting defect. Also, Malzac et al. (1998) [8] reported that the phenotype due to *UBE3A* mutation did not differ regardless of the mutation and they also reported that the clinical phenotype presented by the patient carrying a *UBE3A* mutation is the typical AS phenotype. However, some patients carrying *UBE3A* mutations showed milder phenotype, as they do not present ataxic gait, seizures, microcephaly, and normal EEG [13,15]. We hypothesized



## Additional file

### Additional file 1: DNA sequencing after bisulfite conversion.

A) Shows part of the SNRPN region analyzed in this work. 1. SNRPN sequence before bisulfite conversion; in bold we show the CpG dinucleotides. 2. SNRPN sequence after bisulfite conversion; in red we show the isolated cytosine which were converted into thymine. B) The sequencing obtained for the mother (II.5), patient III.1 and patient III.5 after the bisulfite conversion. \* shows the CpG dinucleotides.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

GAM: carried out the molecular genetic studies (HRM, MS-HRM, DNA sequencing) and drafted the manuscript. CAF and DOV: carried out the HRM. LRG: evaluated the patients. MJM: carried out the clinical exams such as EEG, MRI. WASJ: have given final approval of the version to be published. All authors read and approved the final manuscript.

### Author details

<sup>1</sup>Department of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil. <sup>2</sup>Regional Blood Center of Ribeirao Preto and National Institute of Science and Technology in Cell Therapy, Ribeirao Preto, Brazil. <sup>3</sup>Department of Pediatrics, Federal University of Mato Grosso do Sul, Campo Grande, Brazil. <sup>4</sup>CTC – Centro de Terapia Celular da Fundação Hemocentro de Ribeirao Preto, Laboratório de Genética Molecular e Bioinformática, Depto. De Genética, Rua Tenente Catão Roxo, 250114051-140, Ribeirão Preto, São Paulo, Brazil.

Received: 19 December 2011 Accepted: 13 December 2012

Published: 20 December 2012

## References

1. Clayton-Smith J, Pembrey ME: **Angelman syndrome.** *J Med Genet* 1992, **29**:412–415.
2. Williams CA: **Neurological aspects of the Angelman syndrome.** *Brain Dev* 2005, **27**:88–94.
3. Wagstaff J, Shugart YY, Lalande M: **Linkage analysis in familial Angelman syndrome.** *Am J Hum Genet* 1993, **53**:105–112.
4. Horsthemke B, Wagstaff J: **Mechanisms of imprinting of the Prader-Willi/Angelman region.** *Am J Med Genet* 2008, **146A**:2041–2052.
5. Fang P, Lev-Lehman E, Tsai TF, Matsuura T, Benton CS, Sutcliffe JS, Christian L, Kubota T, Halley DJ, Meijers-Hijboer H, Langlois S, Graham JJ, Beuten J, Willems PJ, Ledbetter DH, Beaudet A: **The spectrum of mutations in UBE3A causing Angelman syndrome.** *Hum Mol Genet* 1999, **8**:129–135.
6. Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Griffith EC, Waldon Z, Maehr R, Ploegh HL, Chowdhury S, Worley PF, Steen J, Greenberg ME: **The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc.** *Cell* 2010, **140**:704–716.
7. White HE, Hall VJ, Cross NCP: **Methylation-sensitive high-resolution melting-curve analysis of the SNRPN gene as a diagnostic screen for Prader-Willi and Angelman syndromes.** *Clin Chem* 2007, **53**:1960–1962.
8. Malzac P, Webber H, Moncla A, Graham JM, Kukulich M, Williams C, Pagon RA, Ramsdell LA, Kishino T, Wagstaff J: **Mutation analysis of UBE3A in Angelman syndrome patients.** *Am J Hum Genet* 1998, **62**:1353–1360.
9. Kubota T, Das S, Christian SL, Baylin SB, Herman JG, Ledbetter DH: **Methylation-specific PCR simplifies imprinting analysis.** *Nat Genet* 1997, **16**:16–17.
10. Wojdacz TK, Dobrovic A: **Methylation sensitive high resolution melting (MS-MS-HRM): a new approach for sensitive and high-throughput assessment of methylation.** *Nucleic Acids Res* 2007, **35**:e41.
11. Kishino T, Lalande M, Wagstaff J: **UBE3A/E6-AP mutations cause Angelman syndrome.** *Nat Genet* 1997, **15**:70–73.
12. Matsuura T, Sutcliffe JS, Frang P, Galjaard R-J, Jiang Y-H, Benton CS, Rommens JM, Beaudet AL: **De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome.** *Nat Genet* 1997, **15**:74–77.
13. Fung DCY, YU B, Cheong KF, Smith A, Trent RJ: **UBE3A “mutations” in two unrelated and phenotypically different Angelman syndrome patients.** *Hum Genet* 1998, **102**:487–492.
14. Baumer A, Balmer B, Schinzel A: **Screening for UBE3A gene mutations in a group of Angelman syndrome patients selected according a non-stringent clinical criteria.** *Hum Genet* 1999, **105**:598–602.
15. Moncla A, Malzac P, Livet M-O, Voelckel M-A, Mancini J, Delaroziere JC, Philip N, Mattei J-F: **Angelman syndrome resulting from UBE3A mutations in 14 patients from eight families: clinical manifestations and genetic counseling.** *J Med Genet* 1999, **36**:554–560.
16. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM: **A family of proteins structurally and functionally related to the E6-AP ubiquitinprotein ligase.** *PNAS* 1995, **92**:2563–2567.
17. Molfetta GA, Hojas MVM, Silva-Jr WA, Wagstaff J, Pina-Neto JM: **Discordant phenotypes in first cousins with UBE3A mutation.** *Am J Med Genet* 2004, **127**(3):258–262.
18. LaSalle JM, Ritchie RJ, Glatt H, Lalande M: **Clonal heterogeneity at allelic methylation sites diagnostic for Prader-Willi and Angelman syndromes.** *PNAS* 1998, **95**(4):1675–1680.
19. Balmer D, LaSalle JM: **Clonal maintenance of imprinted expression of SNRPN and IPW in normal lymphocytes: correlation with allele-specific methylation of SNRPN intron 1 but not intron 7.** *Hum Genet* 2001, **108**(2):116–122.
20. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: **High-resolution genotyping by amplicon melting analysis using LCGreen.** *Clin Chem* 2003, **49**:853–860.

doi:10.1186/1471-2350-13-124

**Cite this article as:** De Molfetta et al.: 1031-1034delTAAC (Leu125Stop): a novel familial UBE3A mutation causing Angelman syndrome in two siblings showing distinct phenotypes. *BMC Medical Genetics* 2012 **13**:124.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

